We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0OCD market cap is 1.48B. The company's latest EPS is NOK 6.2155 and P/E is 13.00.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Revenue | 325.89M | 363.72M | 363.13M | 427.28M | 491.94M |
| Operating Income | 73.98M | 89.77M | 95.49M | 116.28M | 141.25M |
| Net Income | 57.06M | 70.31M | 69.39M | 90.9M | 113.97M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Total Assets | 269.59M | 336.11M | 345.82M | 403.24M | 482.66M |
| Total Liabilities | 62.88M | 99.25M | 88.97M | 97.19M | 114.97M |
| Total Equity | 206.71M | 236.86M | 256.85M | 306.05M | 367.69M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | NOK (kr) | |
| Operating | 55.79M | 80.38M | 74.13M | 128.14M | 113.49M |
| Investing | -16.37M | -13.68M | -10.64M | -11.49M | -21.1M |
| Financing | -44.73M | -46.9M | -58.35M | -59.05M | -70.3M |
| Market Cap | 1.48B |
| Price to Earnings Ratio | 13.00 |
| Price to Sales Ratio | 3.01 |
| Price to Cash Ratio | 10.28 |
| Price to Book Ratio | 4.03 |
| Dividend Yield | - |
| Shares Outstanding | 18.34M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 80.80 |
| 52 Week Low | 80.80 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Medistim Asa |
| Address |
okernveien 94 oslo 0605 |
| Website | https://www.medistim.com |
| Industry | medical instruments & machines (A83) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
